ArticleJournal of gastrointestinal oncology2022
A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer.
Toshiki Masuishi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it